Towards Understanding Bluetongue Outbreaks

Multi-centre sequence analysis reveals origins of economically important virus strain

Amsterdam, August 14, 2008 – A recent article published in Virology, reports the identification of a bluetongue virus strain that caused the northern European Bluetongue outbreak in 2006. Comparison of the virus strain with the sequences of other previously isolated strains showed that it originated in sub-Saharan Africa, rather than from vaccine strains or strains circulating in southern Europe.

Bluetongue (BT) disease or catarrhal fever is a non-contagious, insect borne viral disease of ruminants, mainly sheep. It is characterized by high fever, excessive salivation, swelling of the head and neck which can lead to cyanosis of the tongue (after which the disease is named). BT is caused by the bluetongue virus (BTV) and due to its economic significance BTV has been the subject of extensive molecular, genetic and structural studies. The disease has been observed in Australia, the USA, Africa, the Middle East, Asia and southern Europe. Its occurrence is seasonal in the affected countries, subsiding when temperature drop and hard frosts kill the midges that transmit the disease. It has been spreading northward since the late 90s, perhaps as a result of global warming.

In August 2006, the record temperatures experienced in northern Europe coincided with the first outbreak of BT in the Netherlands, Belgium, Luxemburg, and much of Germany. In the article Peter Mertens and 24 co-authors from six different institutes describe the sequence analysis of the full genome of this BTV strain and compare it to other BTV strains (Virology, doi:10.1016/j.virol.2008.04.028). Their results indicate that despite the high levels of nucleotide identity with other European strains, it represents a new strain introduction, originating from sub-Saharan Africa.

“Such timely and increasingly important insights into the origins of emerging viruses will lead not only to an increased understanding of how viruses like BTV spread, but also to rational vaccine development", said Barbara Sherry, one of the Editors of Virology.

###

Notes to editors:
Maan, S., Maan, N.S., Ross-smith, N., Batten, C.A., Shaw, A.E., Anthony, S.J., Samuel, A.R., Darpel, K.E., Veronesi, E., Oura, C.A.L., Singh, K.P., Nomikou, K., Potgieter, A.C., Attoui, H., van Rooij, E., van Rijn, P., De Clercq, K., Vandenbussche, F., Zientara, S., Bréard, E., Sailleau, C., Beer, M., Hoffman, B., Mellor, P.S., Mertens, P.P.C., 2008. Sequence analysis of bluetongue virus serotype 8 from the Netherlands 2006 and comparison to other European strains. Virology, 377 (2), pp. 308-318.

To receive a copy of the article please contact the press office at newsroom@elsevier.com

About Virology
Launched in 1954, Virology publishes the results of basic research in all branches of virology, including the viruses of vertebrates and invertebrates, plants, bacteria, and yeasts/fungi. The journal features articles on the nature of viruses, on the molecular biology of virus multiplication, on molecular pathogenesis, and on molecular aspects of the control and prevention of viral infections. The approaches and techniques used are expected to encompass those of many disciplines, including molecular genetics, molecular biology, biochemistry, biophysics, structural biology, cell biology, immunology, and morphology. The journal is a leading resource for current information in the field of virology.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact:
Floris de Hon
Elsevier
+31 (0) 20 485 2498
f.hon@elsevier.com